​

Taysha Gene Therapies Ownership | Who Owns Taysha Gene Therapies?

OverviewForecastRevenueFinancialsChartTranscripts

Taysha Gene Therapies Ownership Summary

Taysha Gene Therapies is owned by 19.40% institutional investors, 10.62% insiders, and 69.98% retail investors. Ra capital management is the largest institutional shareholder, holding 7.37% of TSHA shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.16% of its assets in Taysha Gene Therapies shares.

TSHA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTaysha Gene Therapies19.40%10.62%69.98%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management23.56M7.37%$105.29M
Goldman sachs group22.37M7.00%$99.99M
Avoro capital advisors21.70M6.79%$97.00M
Blackrock funding, inc. /de18.37M5.74%$82.09M
Vestal point capital, lp18.00M5.63%$80.46M
Morgan stanley17.97M5.62%$80.31M
Blackrock11.74M5.08%$26.30M
Fmr14.32M4.48%$64.02M
Rtw investments, lp13.68M4.28%$61.15M
Vanguard group13.27M3.76%$72.97M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tybourne capital management (hk)3.70M39.11%$12.10M
B group1.80M5.97%$8.05M
Octagon capital advisors lp8.86M4.38%$39.60M
Ally bridge group (ny)1.90M3.78%$6.21M
Vestal point capital, lp18.00M2.25%$80.46M
Great point partners1.50M2.02%$4.91M
Acuta capital partners439.46K1.39%$1.96M
Quantum private wealth849.21K1.17%$3.80M
Ra capital management23.56M1.12%$105.29M
Casdin capital3.25M1.10%$14.53M

Top Buyers

HolderShares% AssetsChange
Blackrock11.74M0.00%9.15M
Goldman sachs group22.37M0.01%8.68M
Vestal point capital, lp18.00M2.25%4.25M
Ally bridge group (ny)1.90M3.78%1.90M
Norges bank1.84M0.00%1.84M

Top Sellers

HolderShares% AssetsChange
Point72 asset management461.86K0.00%-3.41M
Vr adviser---3.23M
Suvretta capital management---3.22M
Bioimpact capital---2.95M
Toronto dominion bank1.92M0.01%-2.80M

New Positions

HolderShares% AssetsChangeValue
Ally bridge group (ny)1.90M3.78%1.90M$6.21M
Norges bank1.84M0.00%1.84M$10.11M
Vanguard fiduciary trust1.53M0.00%1.53M$6.84M
Moore capital management, lp328.83K0.03%328.83K$1.47M
Readystate asset management lp161.97K0.02%161.97K$529.65K

Sold Out

HolderChange
Quadrant capital group-2.00
Hughes financial services-4.00
Northwestern mutual wealth management-8.00
Tradewinds capital management-20.00
Srs capital advisors-21.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026123-39.41%62,034,790-76.94%190.33%61-53.08%32-27.27%
Dec 31, 2025141-10.76%144,935,051-45.23%410.52%934.49%27-20.59%
Sep 30, 20251537.75%264,590,86716.57%881.53%86-1.15%346.25%
Jun 30, 202514816.54%257,619,95754.48%862.25%9045.16%3310.00%
Mar 31, 202512-90.63%63,845,739-61.79%250.66%7-90.41%1-96.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O6.48M3.16%-
RTW Biotech Opportunities Ord7.80M2.85%7.80M
Vanguard Total Stock Mkt Idx Inv7.51M2.62%-
Vanguard US Total Market Shares ETF4.46M2.17%-
State Street® SPDR® S&P® Biotech ETF6.21M2.16%-62.13K
Fidelity Growth Compy Commingled Pl S5.45M1.90%8.58K
Polar Capital Biotech S Inc5.36M1.86%-
iShares Russell 2000 ETF5.20M1.81%43.85K
Fidelity Growth Company Fund4.18M1.45%-
Xtrackers MSCI World Swap ETF 1C2.47M1.20%-

Recent Insider Transactions

DateNameRoleActivityValue
Apr 10, 2026Nagendran Sukumar President and Head of R&DSell$892.00K
Feb 04, 2026Alam Kamran CHIEF FINANCIAL OFFICERSell$7.48K
Jan 26, 2026Nagendran Sukumar President and Head of R&DSell$124.09K
Jan 23, 2026Nagendran Sukumar President and Head of R&DSell$423.38K
Jan 23, 2026Nolan Sean P. Chief Executive OfficerSell$649.75K

Insider Transactions Trends

DateBuySell
2026 Q2-1
2026 Q1-8
2025 Q4-2
2025 Q3-3
2025 Q21-

TSHA Ownership FAQ

Who Owns Taysha Gene Therapies?

Taysha Gene Therapies shareholders are primarily institutional investors at 19.40%, followed by 10.62% insiders and 69.98% retail investors. The average institutional ownership in Taysha Gene Therapies's industry, Biotech Stocks , is 35.75%, which Taysha Gene Therapies falls below.

Who owns the most shares of Taysha Gene Therapies?

Taysha Gene Therapies’s largest shareholders are Ra capital management (23.56M shares, 7.37%), Goldman sachs group (22.37M shares, 7.00%), and Avoro capital advisors (21.7M shares, 6.79%). Together, they hold 21.15% of Taysha Gene Therapies’s total shares outstanding.

Does Blackrock own Taysha Gene Therapies?

Yes, BlackRock owns 5.08% of Taysha Gene Therapies, totaling 11.74M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.3M$. In the last quarter, BlackRock increased its holdings by 9.15M shares, a 352.10% change.

Who is Taysha Gene Therapies’s biggest shareholder by percentage of total assets invested?

Tybourne capital management (hk) is Taysha Gene Therapies’s biggest shareholder by percentage of total assets invested, with 39.11% of its assets in 3.7M Taysha Gene Therapies shares, valued at 12.1M$.

Who is the top mutual fund holder of Taysha Gene Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Taysha Gene Therapies shares, with 3.16% of its total shares outstanding invested in 6.48M Taysha Gene Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools